Document is current
Any future updates will be listed below
-
Authors
Chou, Chun http://orcid.org/0000-0001-7147-4236
Zhang, Xian
Krishna, Chirag
Nixon, Briana G.
Dadi, Saida
Capistrano, Kristelle J.
Kansler, Emily R.
Steele, Miranda
Han, Jian
Shyu, Amy
Zhang, Jing
Stamatiades, Efstathios G. http://orcid.org/0000-0002-2785-9005
Liu, Ming
Li, Shun
Do, Mytrang H.
Edwards, Chaucie
Kang, Davina S.
Chen, Chin-Tung
Wei, Iris H.
Pappou, Emmanouil P.
Weiser, Martin R.
Garcia-Aguilar, J. http://orcid.org/0000-0003-2451-0948
Smith, J. Joshua
Leslie, Christina S. http://orcid.org/0000-0002-4571-5910
Li, Ming O. http://orcid.org/0000-0002-1383-0535
- License Information
-
More Information
Article History
Received: 18 December 2019
Accepted: 10 March 2022
First Online: 20 April 2022
Competing interests
: MSKCC has filed a patent application regarding use of ILTCK in cancer immunotherapy. M.O.L. is a member of the scientific advisory board of and holds equity or stock options in Amberstone Biosciences Inc. and META Pharmaceuticals Inc.
